Menu
Washingtoner
  • Home
  • Health
  • Artificial Intelligence
  • Technology
  • Entertainment
  • Software
  • Real Estate
  • Information Technology
  • Business
Washingtoner

NanoString's GeoMx Mouse Whole Transcriptome Atlas Expands Leadership in Spatial Genomics by Enabling Genome-Wide RNA Profiling
Washingtoner/10113434

Trending...
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX) - 104
  • Resident Inspect Expands Virtual Property Inspections With AppFolio and Rentvine Integrations
  • Are the Cameras in Spokane Flock or ALPRs?
SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial availability of the Mouse Whole Transcriptome Atlas (WTA) for spatial analysis research using the GeoMx® Digital Spatial Profiler (DSP). This launch extends the GeoMx RNA portfolio, which combines the power of spatial biology and Next Generation Sequencing (NGS), to enable full transcriptome spatial RNA and high-plex protein analysis on the GeoMx DSP.

The GeoMx Mouse WTA provides an unbiased, spatial view of all protein-coding genes and is designed for NGS readout on Illumina sequencers. The WTA extends the GeoMx RNA Assay portfolio from a focus on oncology and immunology to new applications in neuroscience, developmental biology, and additional diverse fields. The mouse WTA utilizes the same workflow and chemistry as other GeoMx products to enable robust and sensitive performance in formalin-fixed paraffin-embedded (FFPE) or Fresh Frozen samples.

"The ability to study – with high sensitivity – regions near plaque formations in Alzheimer's disease mouse models is enabling important findings, including our recent identification of a microglial spatial signature, for example," said Dr. Michael Sasner, senior research scientist and MODEL-AD Center manager at The Jackson Laboratory. "These studies in novel mouse models should enable MODEL-AD to understand how the underlying biological mechanisms of AD may vary across brain regions with age, and to map where AD-related changes in expression start and how they spread with disease progression."

More on Washingtoner
  • Building a Technology Powerhouse-From AI Drones and Global Acquisitions to Defense, Enterprise Software and the Future of Autonomous Operations $ZENA
  • Shelter Structures America backs MATRA Second Life Project to turn retired tent vinyl into homes for displaced families
  • P-Wave Press Announces Becoming Dad: Reflections for New Fathers by L. A. Davenport
  • Logicraft Launches FuelDeck™, AI That Turns Aviation Fuel Tickets Into One Traceable Ledger
  • Inaugural OC Tech Week Draws 3,000 From 12 Countries, Sends Finalist to $1M Startup World Cup

"The GeoMx Mouse WTA is a key milestone for NanoString, bringing unbiased RNA profiling for the primary animal model for discovery research, which represents about 30% of the addressable market," said Chad Brown, senior vice president of Sales and Marketing, NanoString. "The strong enthusiasm for the products in our Technology Access Program highlights the appetite for whole transcriptome spatial analysis on GeoMx DSP."

The GeoMx Mouse WTA platform provides the opportunity to examine the relationship between pathology and gene expression within a tissue section. This technology enables measurement of all gene activity in tissue sections, across brain regions and ages, and to map where disease-related changes in expression occur.

To learn more about NanoString's GeoMx Digital Spatial Profiler, please visit https://www.nanostring.com/products/geomx-digital-spatial-profiler/geomx-dsp.

About NanoString Technologies, Inc.

NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company's nCounter® Analysis System is used in life sciences research and has been cited in more than 4,300 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's GeoMx® Digital Spatial Profiler enables highly multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.

More on Washingtoner
  • Award-Winning American Hotelier Opens Art-Filled Luxury Cottage in Norfolk, England
  • K2 Global / Ozi Amanat Named Among Top 100 AI Venture Capitalists in 2026
  • Community Days at Spokane City Council Celebrating Veteran's Day
  • Dr. Latorial Faison Appointed Poet Laureate of Virginia
  • Sparta Services Named to CRN's 2026 AI Innovators List

For more information, please visit www.nanostring.com.

NanoString, NanoString Technologies, the NanoString logo, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Heritage at Manalapan Announces New 3.875% First-Year Mortgage Rate Buydown (7.11 APR)
  • Haven Treatment Center Pays It Forward with Donation of 150 Food Boxes and Gift Cards to Evergreen
  • AthleteMerch.com Surpasses 100,000 Custom Items Delivered to Fans Nationwide
  • Steve Weclew is Appointed by STS Capital Partners as Managing Director
  • ThriveStack citedby launches Prompt Research to find the prompts buyers ask in AI search
  • New Finnish Affiliate Site Ilmaiskierrokset.com Puts Wager-Free Spins in the Spotlight
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
  • Immerse Yourself in the Historic Tochigi Autumn Festival, Celebrated Every Two Years Since 1874
  • Tacoma: OMWBE Active Certification Class on November 16
  • Ornamental Designer Pro to Attend METALfab 2027, Sponsor Wednesday Opening Reception
  • The Case For Civil Disagreement
  • Resident Inspect Expands Virtual Property Inspections With AppFolio and Rentvine Integrations
  • Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA)
  • AeroNet Deploys netElastic vBNG and CGNAT with Tarana Wireless to Deliver Scalable, Fiber-Class Broadband Across Puerto Rico
  • New Atlas Maps the 38 States Behind Every Conversation
  • Atlanta Company Launches Free, Ad-Free, Nonpartisan Voter Planning App for All 50 States Ahead of the Nov. 3 Election
  • NECP Promotes Chertova to Senior Business Analyst
  • Security Industry Veteran Anthony Rumore Launches AegisLead to Help Security Companies Find Business and Manage Growth
  • Charlie Shaw and Patrick Carragher win SEO Agency of the Year 2026
  • Canadian Woman Plants 1,667 Love Stories in a Field of Peonies That Could Bloom for 100 Years
_catLbl0 _catLbl1

Popular on Washingtoner

  • Spokane: City and Permittable Partner to Support Rebuilding After Wildfires - 264
  • Spokane: City to provide asbestos testing, host community resource meetings - 216
  • Tacoma: In-Person Workshop on October 22 for Local Businesses on the City’s Revolving Loan Fund Process - 181
  • Pre-Seed VC Martin Tobias Makes Fundraising Tool Available to Every Startup CEO as Investor Match - 138
  • Citizens for West Virginia Election Integrity Urges "FOR" on Amendment 1 - 120
  • Final Week to Register for Free Spokane Community Conference - 120
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX) - 104
  • Geospatial Innovation Comes to Sacramento: FOSS4G NA 2026 - 102
  • Holiday Gambling Spending Expected to Rise 12% in December
  • Spokane Police Respond to Fatal Stabbing in Northeast Spokane

Similar on Washingtoner

  • FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
  • Building a Technology Powerhouse-From AI Drones and Global Acquisitions to Defense, Enterprise Software and the Future of Autonomous Operations $ZENA
  • K2 Global / Ozi Amanat Named Among Top 100 AI Venture Capitalists in 2026
  • Pursant Founder Mark Herbick Joins STS Capital Partners as CEO
  • Tampa Web Design Launches New Website for Entrepreneur and Capital Markets Advisor Martin Sumichrast
  • UK Financial Ltd. Announces Maya Preferred PRA as First Fully Verified Asset on MAYA CHAIN; Chainlink Proof of Reserve Integration Planned for Network
  • RAS AP Consulting Advances 1099 Education and Readiness Initiative Through IFOL Training and Finance Technology Showcase
  • Steve Weclew is Appointed by STS Capital Partners as Managing Director
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
  • Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA)
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute